These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 8839666)

  • 1. Effects of omeprazole and cimetidine on the urinary metabolic ratio of proguanil in healthy volunteers.
    Somogyi AA; Reinhard HA; Bochner F
    Eur J Clin Pharmacol; 1996; 50(5):417-9. PubMed ID: 8839666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments.
    Funck-Brentano C; Becquemont L; Lenevu A; Roux A; Jaillon P; Beaune P
    J Pharmacol Exp Ther; 1997 Feb; 280(2):730-8. PubMed ID: 9023285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concordance between proguanil phenotype and CYP2C19 genotype in Chinese.
    Hoskins JM; Shenfield GM; Gross AS
    Eur J Clin Pharmacol; 2003 Nov; 59(8-9):611-4. PubMed ID: 13680037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The hydroxylation of omeprazole correlates with S-mephenytoin and proguanil metabolism.
    Kortunay S; Basci NE; Bozkurt A; Isimer A; Sayal A; Kayaalp SO
    Eur J Clin Pharmacol; 1997; 53(3-4):261-4. PubMed ID: 9476042
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphic oxidative metabolism of proguanil in a Nigerian population.
    Bolaji OO; Sadare IO; Babalola CP; Ogunbona FA
    Eur J Clin Pharmacol; 2002 Nov; 58(8):543-5. PubMed ID: 12451432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of chloroguanide and mephenytoin for the in vivo assessment of genetically determined CYP2C19 activity in humans.
    Partovian C; Jacqz-Aigrain E; Keundjian A; Jaillon P; Funck-Brentano C
    Clin Pharmacol Ther; 1995 Sep; 58(3):257-63. PubMed ID: 7554698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Slow chloroguanide metabolism in Tanzanians compared with white subjects and Asian subjects confirms a decreased CYP2C19 activity in relation to genotype.
    Herrlin K; Massele AY; Rimoy G; Alm C; Rais M; Ericsson O; Bertilsson L; Gustafsson LL
    Clin Pharmacol Ther; 2000 Aug; 68(2):189-98. PubMed ID: 10976550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of honey on CYP3A4, CYP2D6 and CYP2C19 enzyme activity in healthy human volunteers.
    Tushar T; Vinod T; Rajan S; Shashindran C; Adithan C
    Basic Clin Pharmacol Toxicol; 2007 Apr; 100(4):269-72. PubMed ID: 17371531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic cytochrome P450 CYP2C activity in psoriasis: studies using proguanil as a probe compound.
    Helsby NA; Ward SA; Parslew RA; Friedmann PS; Rhodes LE
    Acta Derm Venereol; 1998 Mar; 78(2):81-3. PubMed ID: 9534880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine inhibits the CYP2C19-catalysed metabolism of proguanil in vitro.
    Rasmussen BB; Nielsen TL; Brøsen K
    Eur J Clin Pharmacol; 1998; 54(9-10):735-40. PubMed ID: 9923577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.
    Wanwimolruk S; Bhawan S; Coville PF; Chalcroft SC
    Eur J Clin Pharmacol; 1998 Jul; 54(5):431-5. PubMed ID: 9754989
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population.
    Hoskins JM; Shenfield GM; Gross AS
    Br J Clin Pharmacol; 1998 Nov; 46(5):499-504. PubMed ID: 9833604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination.
    Tennezé L; Verstuyft C; Becquemont L; Poirier JM; Wilkinson GR; Funck-Brentano C
    Clin Pharmacol Ther; 1999 Dec; 66(6):582-8. PubMed ID: 10613613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between CYP2C19 genotype and proguanil oxidative polymorphism.
    Coller JK; Somogyi AA; Bochner F
    Br J Clin Pharmacol; 1997 Jun; 43(6):659-60. PubMed ID: 9205829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide.
    Jeppesen U; Rasmussen BB; Brøsen K
    Clin Pharmacol Ther; 1997 Sep; 62(3):279-86. PubMed ID: 9333103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of (S)-mephenytoin and proguanil oxidation in vitro: contribution of several CYP isoforms.
    Coller JK; Somogyi AA; Bochner F
    Br J Clin Pharmacol; 1999 Aug; 48(2):158-67. PubMed ID: 10417492
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrinsic efficacy of proguanil against falciparum and vivax malaria independent of the metabolite cycloguanil.
    Kaneko A; Bergqvist Y; Takechi M; Kalkoa M; Kaneko O; Kobayakawa T; Ishizaki T; Björkman A
    J Infect Dis; 1999 Apr; 179(4):974-9. PubMed ID: 10068594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin hydroxylase.
    Birkett DJ; Rees D; Andersson T; Gonzalez FJ; Miners JO; Veronese ME
    Br J Clin Pharmacol; 1994 May; 37(5):413-20. PubMed ID: 8054246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism.
    Somogyi AA; Reinhard HA; Bochner F
    Br J Clin Pharmacol; 1996 Mar; 41(3):175-9. PubMed ID: 8866915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multiple dose pharmacokinetics of proguanil.
    Helsby NA; Edwards G; Breckenridge AM; Ward SA
    Br J Clin Pharmacol; 1993 Jun; 35(6):653-6. PubMed ID: 8329294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.